- Home
- FORR vs EDIT Comparison
FORR vs EDIT Comparison
Compare FORR & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORR
- EDIT
- Stock Information
- Founded
- FORR 1983
- EDIT 2013
- Country
- FORR United States
- EDIT United States
- Employees
- FORR N/A
- EDIT N/A
- Industry
- FORR Diversified Commercial Services
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FORR Consumer Discretionary
- EDIT Health Care
- Exchange
- FORR Nasdaq
- EDIT Nasdaq
- Market Cap
- FORR 359.0M
- EDIT 327.0M
- IPO Year
- FORR 1996
- EDIT 2016
- Fundamental
- Price
- FORR $16.09
- EDIT $2.66
- Analyst Decision
- FORR
- EDIT Buy
- Analyst Count
- FORR 0
- EDIT 13
- Target Price
- FORR N/A
- EDIT $9.38
- AVG Volume (30 Days)
- FORR 80.0K
- EDIT 2.3M
- Earning Date
- FORR 11-05-2024
- EDIT 11-04-2024
- Dividend Yield
- FORR N/A
- EDIT N/A
- EPS Growth
- FORR N/A
- EDIT N/A
- EPS
- FORR N/A
- EDIT N/A
- Revenue
- FORR $442,518,000.00
- EDIT $61,759,000.00
- Revenue This Year
- FORR N/A
- EDIT N/A
- Revenue Next Year
- FORR $2.23
- EDIT N/A
- P/E Ratio
- FORR N/A
- EDIT N/A
- Revenue Growth
- FORR N/A
- EDIT 150.95
- 52 Week Low
- FORR $14.38
- EDIT $2.59
- 52 Week High
- FORR $27.89
- EDIT $11.69
- Technical
- Relative Strength Index (RSI)
- FORR 49.49
- EDIT 35.77
- Support Level
- FORR $14.42
- EDIT $3.07
- Resistance Level
- FORR $17.63
- EDIT $3.38
- Average True Range (ATR)
- FORR 0.72
- EDIT 0.23
- MACD
- FORR 0.22
- EDIT -0.03
- Stochastic Oscillator
- FORR 52.62
- EDIT 8.64
About FORR Forrester Research Inc.
Forrester Research Inc is a United States-based company that provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.